TABLE 1

Patient Characteristics and Localization of Pathologic PSMA Uptake Detected by 68Ga-PSMA-11 PET/CT and 18F-JK-PSMA-7 PET/CT in Initial Cohort of 10 Patients (Patients 1–5)

Patient no.Age (y)PSA (ng/mL)IndicationGleason scoreDosePSMA+Therapeutic consequenceVerification
LocalNodalDistant
1761.48*Taking bicalutamide; intensification of ADT?4 + 4Salvage-RT; bicalutamide as before without GnRH analogPSA decrease to 0.23 ng/mL; M osseous confirmed by previous PET/CT
 68Ga-PSMA160100
 18F-JK-PSMA363101
2670.7BCR after prostatectomy4 + 3RT of upper left iliac LNPSA decrease to 0.5 ng/mL 4 mo after RT without ADT; after 10 mo PSA 0.6 ng/mL
 68Ga-PSMA17201 left iliac0
 18F-JK-PSMA35502 left iliac0
3661.03BCR after prostatectomy and radiotherapy3 + 4Wait and see; 68Ga PSMA PET/CT interpreted as unspecific; no indication for LAD or RTPSA 1.06 ng/mL after 6 mo
 68Ga-PSMA16801 retroperitoneal†0
 18F-JK-PSMA347000
4741.1BCR after prostatectomy3 + 4LAD; after progression (PSA, PET/CT) RT of LN areaLN not confirmed by histology (0/4); PSA increase to 2.6 ng/mL after 8 mo; progression proven by external 68Ga-PSMA-11 PET/CT (2 PSMA-positive LN left iliac)
 68Ga-PSMA134000
 18F-JK-PSMA35001 left iliac0
5634.7BCR after prostatectomy4 + 3Salvage RT of prostate fieldPSA decrease to 0.57 ng/mL
 68Ga-PSMA157100
 18F-JK-PSMA329100

  • ↵* With ADT.

  • ↵† Not confirmed by follow-up care.

  • RT = radiotherapy; GnRH = gonadotropin releasing hormone; M = metastasis; LN = lymph node; LAD = lymphadenectomy; n.a. = not available.

  • Patient 6 did not receive 68Ga-PSMA-11 PET/CT and was not included in our direct comparison.